Avacta Group PLC Result of Annual General Meeting (7412U)
20 January 2017 - 10:35PM
UK Regulatory
TIDMAVCT
RNS Number : 7412U
Avacta Group PLC
20 January 2017
20 January 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Result of Annual General Meeting
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, announces that at the Annual
General Meeting held earlier today, all resolutions were duly
passed.
The full text of each resolution, is set out in the Notice of
Annual General Meeting, included in the 2016 Annual Report, which
is available on the Company's website www.avacta.com.
ENDS
Notes to Editors
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 844
Alastair Smith, Chief Executive 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0) 207
Geoff Nash / Giles Rolls - Nominated 220 0500
Adviser www.finncap.com
Tim Redfern / Alice Lane - Corporate
Broking
Tel: +44 (0) 203
WG Partners 705 9318
David Wilson Tel: +44 (0) 203
Nigel Barnes 705 9217
Claes Spang www.wgpartners.co.uk
FTI Consulting (Financial Media Tel: +44 (0) 203
and IR) 727 1000
Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $75bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of targets to enable diagnostics, research assays
and therapeutics.
Avacta has a pre-clinical therapeutic development programme with
an in-house focus on immuno-oncology and bleeding disorders as well
as partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGPGUGWGUPMGGU
(END) Dow Jones Newswires
January 20, 2017 06:35 ET (11:35 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024